Phylogenetic analysis of complete genome sequences of hepatitis B virus from an Afro-Colombian community: presence of HBV F3/A1 recombinant strain
Carregando...
Citações na Scopus
13
Tipo de produção
article
Data de publicação
2012
Título da Revista
ISSN da Revista
Título do Volume
Editora
BIOMED CENTRAL LTD
Autores
Citação
VIROLOGY JOURNAL, v.9, article ID 244, 7p, 2012
Resumo
Background: Hepatitis B virus (HBV) infection is one of the most prevalent viral infections in humans and represents a serious public health problem. In Colombia, our group reported recently the presence of subgenotypes F3, A2 and genotype G in Bogota. The aim of this study was to characterize the HBV genotypes circulating in Quibdo, the largest Afro-descendant community in Colombia. Sixty HBsAg-positive samples were studied. A fragment of 1306 bp (S/POL) was amplified by nested PCR. Positive samples to S/POL fragment were submitted to PCR amplification of the HBV complete genome. Findings: The distribution of HBV genotypes was: A1 (52.17%), E (39.13%), D3 (4.3%) and F3/A1 (4.3%). An HBV recombinant strain subgenotype F3/A1 was found for the first time. Conclusions: This study is the first analysis of complete HBV genome sequences from Afro-Colombian population. It was found an important presence of HBV/A1 and HBV/E genotypes. A new recombinant strain of HBV genotype F3/A1 was reported in this population. This fact may be correlated with the introduction of these genotypes in the times of slavery.
Palavras-chave
Hepatitis B virus, Subgenotype A1, Genotype E, Subgenotype D3, Bayesian analysis, Recombinant subgenotype F3/A1, Colombia
Referências
- Alvarado-Mora MV, 2011, PLOS ONE, V6
- Andernach IE, 2009, EMERG INFECT DIS, V15, P1222, DOI 10.3201/eid1508.081642
- ARBOLEDA M, 1995, T ROY SOC TROP MED H, V89, P481, DOI 10.1016/0035-9203(95)90074-8
- Chomczynski P, 2006, NAT PROTOC, V1, P581, DOI 10.1038/nprot.2006.83
- Devesa M, 2008, J MED VIROL, V80, P20, DOI 10.1002/jmv.21024
- Drummond AJ, 2007, BMC EVOL BIOL, V7, DOI 10.1186/1471-2148-7-214
- Duarte MC, 2010, TROP MED INT HEALTH, V15, P924, DOI 10.1111/j.1365-3156.2010.02560.x
- Edgar RC, 2004, BMC BIOINFORMATICS, V5, P1, DOI 10.1186/1471-2105-5-113
- FAY OH, 1990, VACCINE, V8, pS100
- Gomes-Gouvea MS, 2005, CHARACTERIZATION COM, P130
- Hannoun C, 2005, J GEN VIROL, V86, P2163, DOI 10.1099/vir.0.80972-0
- Hubschen JM, 2011, CLIN MICROBIOL INFEC, V17, P88, DOI 10.1111/j.1469-0691.2010.03205.x
- Kramvis A, 2007, HEPATOL RES, V37, pS27, DOI 10.1111/j.1872-034X.2007.00100.x
- Kramvis A, 2002, J GEN VIROL, V83, P835
- Lee WM, 1997, NEW ENGL J MED, V337, P1733, DOI 10.1056/NEJM199712113372406
- Mbayed VA, 2009, ARCH VIROL, V154, P525, DOI 10.1007/s00705-009-0328-6
- Mora MVA, 2011, INFECT GENET EVOL, V11, P103, DOI 10.1016/j.meegid.2010.10.003
- Mora MVA, 2010, J GEN VIROL, V91, P501, DOI 10.1099/vir.0.015958-0
- Motta-Castro ARC, 2005, J MED VIROL, V77, P188, DOI 10.1002/jmv.20435
- Norder H, 2004, INTERVIROLOGY, V47, P289, DOI 10.1159/000080872
- Olinger CM, 2006, J GEN VIROL, V87, P1163, DOI 10.1099/vir.0.81614-0
- Pourkarim MR, 2010, J CLIN VIROL, V47, P93, DOI 10.1016/j.jcv.2009.09.032
- Purdy MA, 2008, J GEN VIROL, V89, P1179, DOI 10.1099/vir.0.83392-0
- Simmonds P, 2005, J VIROL, V79, P15467, DOI 10.1128/JVI.79.24.15467-15476.2005
- Stuyver L, 2000, J GEN VIROL, V81, P67
- Sugauchi F, 2002, J VIROL, V76, P5985, DOI 10.1128/JVI.76.12.5985-5992.2002
- Tanaka J, 2000, VACCINE, V18, pS17, DOI 10.1016/S0264-410X(99)00455-7
- Yu H, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009297